BSEBoard Meeting6d ago · 27 Aug 2026, 08:24 pm
Asston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/09/2026 ,inter alia, to consider and approve 1. Appointment of M/s ....
Asston Pharmaceuticals Ltd · 544445
✦ AI SummaryMgmt Change
Asston Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 04/09/2026 to consider and approve various matters, including the appointment of a new statutory auditor, increase in remuneration of directors, and the date and draft notice of the 7th Annual General Meeting.
Analysis Scores
Earnings Impact2/10
Growth Catalyst3/10
Governance Concern4/10
Regulatory Risk2/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Asston Pharmaceuticals Ltd - 544445 - Board Meeting Intimation for Convening 7Th Annual General Meeting Of The Company
Attachments (1)
📄pdf
Download →
a31fb08b-2352-4daa-9c70-cb228adabff9.pdf
View document text
ASSTON PHARMACEUTICALS LIMITED
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)
To, Date: 27th August, 2026
BSE Limited
Listing / Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai, 400001
BSE Code: 544445
ISIN: INE0SJX01015
Sub: Board Meeting Intimation under Regulation 29 of the SEBI (Listing Obligation and Disclosure
Requirements) Regulations, 2015.
Dear Sir/ Madam,
Pursuant to Regulation 29(1) of the SEBI Listing Regulations, we wish to inform you that a Meeting
of the Board of Directors (the "Board") of the Company will be held on Friday, 04th September,
2026, to consider and approve the following matters:
1. To consider and approve the appointment of M/s Panchal S K & Associates (Peer Review
Certificate No.: 018089 and Firm Registration No.: 145989W) as Statutory Auditor of the
Company;
2. To consider and ascertain the directors retiring by rotation;
3. To consider and approve an increase in remuneration of Mr. Ashish Narayan Sakalkar Din
06601011, Managing Director of the Company;
4. To consider and approve an increase in remuneration of Mrs. Saili Jayaram More Din 02691527,
Whole Time Director and CEO of the Company;
5. To consider and approve an increase in remuneration of Mr. Sachin Chandrakant Badakh Din
08685214, Non-Executive Director of the Company;
6. To consider and approve the date and draft notice of the 7th Annual General Meeting of the
Company;
7. Other incidental matters
Kindly take the same on your records.
Thanking you,
For and on behalf of the Board of Directors
Rishi Upadhaya
Company Secretary & Compliance Officer
A74324
CIN: U24304MH2019PLC324187
Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi
Mumbai, Thane, Maharashtra, 400614, India
Phone No.: 022-49731419 / 49731411, Email id:
aston.tech14@gmail.com/compliance@asstonpharmaceuticals.com
Web: www.asstonpharmaceuticals.com